| SPERO THERAPEUTICS |
| USA |
| Gesundheit |
| US84833T1034 / A2H63F |
| 2HA (Frankfurt) / SPRO (NASDAQ) |
| FRA:2HA, ETR:2HA, 2HA:GR, NASDAQ:SPRO |
| - |
| https://sperotherapeutics.. |
|
Spero Therapeutics Inc. is a biopharmaceutical company focused on developing novel treatments for infectious diseases, particularly those caused by antibiotic-resistant bacteria. The primary function of Spero Therapeutics is to address the growing gl..
>Volltext.. |
| 106.6 Mio. EUR |
| 59.99 Mio. EUR |
| 47.79 Mio. EUR |
| 6.77 Mio. EUR |
| 13.29 Mio. EUR |
| 0.24 EUR |
| 2.16 Mio. EUR |
| 48.98 Mio. EUR |
| 6.32 Mio. EUR |
| 10.23 |
| 81.19% |
| - |
| - |
| - |
| - |
| - |
| SPERO THERAPEUTICS, SPERO THERAPEUTIC |
| 19.06.26 |
|
||||
|
||||
|
||||
|
||||
|